Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
AstraZeneca PLC (AZN) is a leading drug manufacturers-general business based in the US. It opened the day at $55.45 after a previous close of $55.21. During the day the price has varied from a low of $55.43 to a high of $55.87. The latest price was $55.78 (25 minute delay). AstraZeneca is listed on the NASDAQ and employs 76,100 staff. All prices are listed in US Dollars.
Since the stock market crash in March caused by coronavirus, AstraZeneca's share price has had significant positive movement.
Its last close price was $55.78, which is 10.05% up on its pre-crash value of $50.17 and 54.29% up on the lowest point reached during the March crash when the shares fell as low as $36.15.
If you had bought $1,000 worth of AstraZeneca shares at the start of February 2020, those shares would have been worth $799.26 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1.00.
In mid-November, AstraZeneca announced that its COVID-19 vaccine, which was developed in partnership with the University of Oxford, has an average efficacy of 70%. In some clinical tests, the vaccine was 90% effective. The company says it will have 3 billion doses of the vaccine available in 2021.
The company’s vaccine follows news that Moderna and Pfizer have each developed vaccines. Shares of AstraZeneca (AZN) were down following the news.
|52-week range||$46.48 - $63.20|
|50-day moving average||$49.44|
|200-day moving average||$51.87|
|Wall St. target price||$63.60|
|Dividend yield||$2.8 (5.18%)|
|Earnings per share (TTM)||$1.52|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-05-10)||2.57%|
|1 month (2021-04-16)||9.92%|
|3 months (2021-02-17)||8.41%|
|6 months (2020-11-17)||1.48%|
|1 year (2020-05-15)||4.43%|
|2 years (2019-05-17)||47.63%|
|3 years (2018-05-17)||53.06%|
|5 years (2016-05-17)||93.73%|
Valuing AstraZeneca stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AstraZeneca's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
AstraZeneca's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 36x. In other words, AstraZeneca shares trade at around 36x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
AstraZeneca's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3627. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AstraZeneca's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
AstraZeneca's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $6.7 billion.
The EBITDA is a measure of a AstraZeneca's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$27.6 billion|
|Operating margin TTM||14.85%|
|Gross profit TTM||$21.4 billion|
|Return on assets TTM||4.19%|
|Return on equity TTM||29.67%|
|Market capitalisation||$143.4 billion|
TTM: trailing 12 months
There are currently 118.1 million AstraZeneca shares held short by investors – that's known as AstraZeneca's "short interest". This figure is 10.1% up from 107.3 million last month.
There are a few different ways that this level of interest in shorting AstraZeneca shares can be evaluated.
AstraZeneca's "short interest ratio" (SIR) is the quantity of AstraZeneca shares currently shorted divided by the average quantity of AstraZeneca shares traded daily (recently around 10.1 million). AstraZeneca's SIR currently stands at 11.72. In other words for every 100,000 AstraZeneca shares traded daily on the market, roughly 11720 shares are currently held short.
However AstraZeneca's short interest can also be evaluated against the total number of AstraZeneca shares, or, against the total number of tradable AstraZeneca shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case AstraZeneca's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 AstraZeneca shares in existence, roughly 40 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable AstraZeneca shares, roughly 0 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against AstraZeneca.
Find out more about how you can short AstraZeneca stock.
Dividend payout ratio: 60.74% of net profits
Recently AstraZeneca has paid out, on average, around 60.74% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.65% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AstraZeneca shareholders could enjoy a 2.65% return on their shares, in the form of dividend payments. In AstraZeneca's case, that would currently equate to about $2.8 per share.
AstraZeneca's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
AstraZeneca's most recent dividend payout was on 28 March 2021. The latest dividend was paid out to all shareholders who bought their shares by 24 February 2021 (the "ex-dividend date").
AstraZeneca's shares were split on a 2:1 basis on 26 July 2015. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your AstraZeneca shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for AstraZeneca shares which in turn could have impacted AstraZeneca's share price.
Over the last 12 months, AstraZeneca's shares have ranged in value from as little as $46.48 up to $63.2033. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AstraZeneca's is 0.1932. This would suggest that AstraZeneca's shares are less volatile than average (for this exchange).
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; and Alchemab to enhance prostate cancer research. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999.
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.